Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target

September 6, 2024

Sponsored By

How effective is Summit Therapeutics' lung cancer immunotherapy? Why are obesity drugmakers turning back to a two-decade-old idea? And how long will Elaine last as a new (official) co-host?

We talk about all that and more on this week's episode of "The Readout LOUD," STAT's biotech podcast. We discuss the next big trend in obesity drug development — treatments that target the amylin hormone. Companies argue that these types of drugs could lead to less nausea and muscle loss, and the first big readout is coming later this year.

We also chat about an upcoming presentation from Summit Therapeutics on its cancer drug that beat Merck's Keytruda, mixed data from Recursion's lead AI-derived drug candidate, and more news in the life sciences.

LISTEN NOW

For more on amylin obesity drugs, go here; for a detailed preview on Summit's presentation, go here; for more on Recursion's mixed results, go here; and to learn more about the full data from Alnylam's HELIOS-B trial , go here.